Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model

Journal of Cardiovascular Pharmacology

Volumn 18, Issue 1, 1991, Pages 111-119

  Martin, U ^a   Fischer, S ^a   Kohnert, U ^a   Rudolph, R ^a   Sponer, G ^a   Stern, A ^a   Strein, K ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Dogs; Hemostasis system; Pharmacokinetics; Thrombolysis; TPA variant

Indexed keywords

ALTEPLASE; RECOMBINANT PLASMINOGEN ACTIVATOR; RETEPLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DRUG BLOOD LEVEL; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL;

ANESTHESIA; ANIMAL; ANTIPLASMIN; BLEEDING TIME; CORONARY CIRCULATION; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; FEMALE; FIBRINOGEN; FIBRINOLYTIC AGENTS; HEMOSTASIS; MALE; PLASMINOGEN; PLASMINOGEN ACTIVATORS; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0025786951     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/00005344-199107000-00015     Document Type: Article

References (23)

1. Verstraete M, Brower RW, Collen D, et al. Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet 1985;2:965-9.
2. Armstrong PW, Baigrie RS, Daly PA, et al. Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. J Am Coll Cardiol 1989;13:1469-76.
3. Wilcox RG, Olsson CG, Skene AM, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet 1988;2:525-39.
4. GISSI Study Group. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-401.
5. Garabedian HD, Gold HK, Leinbach RC, et al. Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. J Am Coll Cardiol 1987;9:599-607.
6. Tebbe U, Tanswell P, Seifried E, et al. Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol 1988;64:448-53.
7. Shebuski RJ, Smith JM, Storer BL, et al. Influence of selective endoperoxide/thromboxane A, receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog. J Pharmacol Exp Ther 1988;246:790-6.
8. Kopia GA, Kopaciewicz LJ, Ohlstein EH, et al. Combination of the thromboxane receptor antagonist, sulotroban (BM 13.177; SK&F 95587), with streptokinase: demonstration of thrombolytic synergy. J Pharmacol Exp Ther 1989;250:887-95.
9. Verheijen JH, Mullaart E, Chang GTG, et al. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromh Haemost 1982;48:266-9.
10. Lill H. Biochemische und physiologische Grundlagen zum Gewebe-Plasminogenaktivator (t-PA). Z Ges Inner Med 1987;42:478-86.
11. Kohnert U, Rudolph R, Prinz H, et al. Production of a recombinant human tissue plasminogen activator variant (BM 06.022) from Escherichia coli using a novel renaturation technology. Fibrinolysis 1990;4(suppl 3):44.
12. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957;17:237-46.
13. Friberger P, Knös M. Plasminogen determination in human plasma. In: Scully MF, ed. Chromogenic peptide substrates: chemistry and clinical usage. Edinburgh: Churchill Livingstone, 1979:128-40.
14. Alkjaersig N, Fletcher AP, Sherry S. The mechanism of clot dissolution by plasmin. J Clin Invest 1959;38:1086-95.
15. Edy J, Collen D, Verstraete M. Quantitation of the plasma protease inhibitor antiplasmin with the chromogenic substrate. In: Davidson JF, Rowan RM, Samama MM, Desnoyers PC, eds. Progress in Chemical Fibrinolysis and Thrombolysis, vol 3. New York: Raven Press, 1978:315-22.
16. Thomas R, Hessel EA, Dillard DH, et al. Standardized template bleeding time in dogs. J Surg Res 1979;27:244-9.
17. Kopia GA, Kopaciewicz LJ, Fong KL, et al. Evaluation of the acute hemodynamic effects and pharmacokinetics of coronary thrombolysis produced by intravenous tissue-type plasminogen activator in the anesthetized dog. J Cardiovasc Pharmacol 1988;12:308-16.
18. Fong KL, Crysler CS, Mico BA, et al. Dose-dependent pharmacokinetics of recombinant tissue-type plasminogen activator in anesthetized dogs following intravenous infusion. Drug Metab Dispos 1988;16:201-6.
19. Wu Z, van de Werf F, Stassen T, et al. Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like, and first kringle domains (amino acids 6-173) in a canine model. J Cardiovasc Pharmacol 1990;16:197-203.
20. Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti-thrombotic agents. Thromb Res 1980;17:841-53.
21. Jackson CV, Crowe VG, Craft TJ, et al. Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis. Circulation 1990;82:930-40.
22. Shebuski RJ, Sitko GR, Claremon DA, et al. Inhibition of factor Xllla in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator. Blood 1990;75:1455-9.
23. Shebuski RJ, Stabilito IJ, Sitko GR, et al. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the arg-gly-asp-containing peptide bitistatin in a canine model of coronary thrombosis. Circulation 1990;82:169-77.